{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:23:53Z","timestamp":1792423433296,"version":"4.5.0"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004767","name":"University of Science and Technology Liaoning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105015","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:01:14Z","timestamp":1762833674000},"page":"105015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Antibody-drug conjugates in oncology: A spotlight on overcoming resistance"],"prefix":"10.1016","volume":"217","author":[{"given":"Xiaoxiao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105015_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib2","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.19.00858","article-title":"Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP foundation trial FB-10","volume":"37","author":"Abraham","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib5","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib7","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.critrevonc.2025.105015_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCP0EN6AQMWETZZ","article-title":"Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition","volume":"136","author":"Bartlett","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib10","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-15-2499","article-title":"Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer","volume":"22","author":"Baselga","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1080\/00498254.2022.2141667","article-title":"ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)","volume":"52","author":"Beaumont","year":"2022","journal-title":"Xenobiotica fate Foreign Compd. Biol. Syst."},{"key":"10.1016\/j.critrevonc.2025.105015_bib12","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/anie.201106527","article-title":"A traceless vascular-targeting antibody-drug conjugate for cancer therapy","volume":"51","author":"Bernardes","year":"2012","journal-title":"Angew. Chem. (Int. Ed. Engl. )"},{"key":"10.1016\/j.critrevonc.2025.105015_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.105015_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13046-020-01797-3","article-title":"Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study","volume":"39","author":"Bon","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA7000","article-title":"Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study","volume":"42","author":"Borchmann","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib16","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1158\/0008-5472.CAN-20-3822","article-title":"Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy","volume":"81","author":"Bordeau","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib17","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","article-title":"Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2\/HER2-positive metastatic breast cancer: a phase 1b clinical trial","volume":"4","author":"Borges","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib18","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","article-title":"Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade","volume":"81","author":"Boshuizen","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib19","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib20","doi-asserted-by":"crossref","unstructured":"Bulat, I., Moore, K.N., Haceatrean, A., Chung, J.W., Rajagopalan, P., Xia, C., Laurent, D., Childs, B.H., and Santin, A. Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Journal of Clinical Oncology 36, 5571-5571.","DOI":"10.1200\/JCO.2018.36.15_suppl.5571"},{"key":"10.1016\/j.critrevonc.2025.105015_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-22-0013","article-title":"Overcoming resistance to anti-nectin-4 antibody-drug conjugate","volume":"21","author":"Cabaud","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib22","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.18632\/oncotarget.27766","article-title":"Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer","volume":"11","author":"Cardillo","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.105015_bib23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1541-7786.MCR-21-0545","article-title":"mTOR Inhibition and T-DM1 in HER2-positive breast cancer","volume":"20","author":"Casadevall","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2024.42.4_suppl.690","article-title":"Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer","volume":"42","author":"Chang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib25","first-page":"683","article-title":"Genetic heterogeneity' in HER2\/neu testing by fluorescence in situ hybridization: a study of 2,522 cases","volume":"25","author":"Chang","year":"2012","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.critrevonc.2025.105015_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2025.105015_bib27","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1535-7163.MCT-16-0219","article-title":"Combining ABCG2 inhibitors with IMMU-132, an anti-trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers","volume":"15","author":"Chang","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.105015_bib29","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 Downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.critrevonc.2025.105015_bib31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acs.bioconjchem.1c00029","article-title":"Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody-drug conjugates","volume":"32","author":"Chuprakov","year":"2021","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.critrevonc.2025.105015_bib32","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1039\/C7SC05266A","article-title":"Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation","volume":"9","author":"Cini","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.critrevonc.2025.105015_bib33","doi-asserted-by":"crossref","unstructured":"Ciruelos, E.M., Pascual, T., Blancas, I., Borrell, M., Villanueva-V\u00e1zquez, R., Adamo, B., Bianchi, M.A., C\u00f3rdoba, L.C., Oliv\u00e9, M.M., Cejalvo, J.M., et al. 2025. SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+\/HER2- advanced or metastatic breast cancer. 43, TPS1123-TPS1123.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS1123"},{"key":"10.1016\/j.critrevonc.2025.105015_bib34","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.105015_bib35","doi-asserted-by":"crossref","unstructured":"Connors, J.M., Jurczak, W., Straus, D.J., Ansell, S.M., Kim, W.S., Gallamini, A., Younes, A., Alekseev, S., Ill\u00e9s, \u00c1., Picardi, M., , 2018. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma. 378, pp. 331-344..","DOI":"10.1056\/NEJMoa1708984"},{"key":"10.1016\/j.critrevonc.2025.105015_bib36","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2020.1796","article-title":"Efficacy and safety of trastuzumab emtansine plus capecitabine vs trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial","volume":"6","author":"Cort\u00e9s","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D'Amico","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody-drug conjugates: promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.critrevonc.2025.105015_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010154","article-title":"Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs","volume":"14","author":"D\u00edaz-Rodr\u00edguez","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.105015_bib41","first-page":"2721","article-title":"Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105015_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41579-018-0048-6","article-title":"Multidrug efflux pumps: structure, function and regulation","volume":"16","author":"Du","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib43","doi-asserted-by":"crossref","unstructured":"Du, Y., Zhang, J., Liu, J., Li, W., Zhang, Q., Lo, L., Yin, Y., Zhao, Y., Zhuang, Z., Wang, X., , 2025. JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies. 43, pp. 1028-1028..","DOI":"10.1200\/JCO.2025.43.16_suppl.1028"},{"key":"10.1016\/j.critrevonc.2025.105015_bib44","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2174\/1568026619666190618130008","article-title":"Targeting tubulin-colchicine site for cancer therapy: inhibitors, antibody- drug conjugates and degradation agents","volume":"19","author":"Duan","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.critrevonc.2025.105015_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.105015_bib46","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/bc900315y","article-title":"Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates","volume":"21","author":"Erickson","year":"2010","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.critrevonc.2025.105015_bib48","first-page":"157","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antib. Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","article-title":"HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells","volume":"20","author":"Figueroa-Vazquez","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib50","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.105015_bib51","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.18.01511","article-title":"TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases","volume":"37","author":"Freedman","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib52","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2021.39.15_suppl.4528","article-title":"Study EV-103: update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"39","author":"Friedlander","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib55","article-title":"AJICAP second generation: improved chemical site-specific conjugation technology for antibody-drug conjugate production","volume":"34","author":"Fujii","year":"2023","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.critrevonc.2025.105015_bib56","doi-asserted-by":"crossref","unstructured":"Galsky, M.D., Del Conte, G., Foti, S., Yu, E.Y., Machiels, J.-P.H., Doger, B., Necchi, A., De Braud, F.G., Hamilton, E.P., Hennequin, A., et al. 2022. Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). Journal of Clinical Oncology 40, 438-438.","DOI":"10.1200\/JCO.2022.40.6_suppl.438"},{"key":"10.1016\/j.critrevonc.2025.105015_bib57","doi-asserted-by":"crossref","unstructured":"Garrido-Castro, A.C., Gorthi, A., Kim, S.E., D'Ippolito, A., Nanda, R., Abdou, Y., Clark, A.S., Sacks, R.L., O'Connor, T.P., Sinclair, N., , 2025. Cell-free circulating chromatin profiling for epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer. 43, pp. 1081-1081.","DOI":"10.1200\/JCO.2025.43.16_suppl.1081"},{"key":"10.1016\/j.critrevonc.2025.105015_bib58","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ijc.30569","article-title":"Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix","volume":"140","author":"G\u00e9bleux","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib60","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clbc.2021.03.005","article-title":"A phase I\/Ib trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-positive advanced breast cancer after trastuzumab and taxane therapy","volume":"21","author":"Haley","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib62","article-title":"Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers","volume":"79","author":"Hamblett","year":"2019","journal-title":"C. R."},{"key":"10.1016\/j.critrevonc.2025.105015_bib63","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.105015_bib64","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","volume":"21","author":"Hartley","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib65","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.105015_bib66","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-017-4453-8","article-title":"HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma","volume":"166","author":"Hou","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.105015_bib67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10549-021-06384-4","article-title":"A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+\u2009tumors in hPD-1 transgenic mouse model and contributes immune memory formation","volume":"191","author":"Huang","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.105015_bib68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2007.06883.x","article-title":"High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate","volume":"140","author":"Ingle","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ebiom.2019.04.061","article-title":"Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1","volume":"43","author":"Islam","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2025.105015_bib70","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib71","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-018-4792-0","article-title":"Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy","volume":"171","author":"Jain","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.105015_bib72","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.2022.40.4_suppl.295","article-title":"Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced\/metastatic HER2+ gastric cancer (GC)\/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03","volume":"40","author":"Janjigian","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib74","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","article-title":"Preclinical characterization and phase I study of an anti-HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2+ malignancies","volume":"10","author":"Janku","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib75","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"10.1016\/j.critrevonc.2025.105015_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib77","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.euo.2024.12.006","article-title":"Genomic biomarkers associated with enfortumab vedotin outcomes for patients with advanced urothelial carcinoma: analysis of UNITE study data","volume":"8","author":"Jindal","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ph13090245","article-title":"Antibody-drug conjugates: the last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.critrevonc.2025.105015_bib79","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib80","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12885-015-1772-1","article-title":"Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells","volume":"15","author":"Kan","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105015_bib82","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/ijc.30276","article-title":"Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer","volume":"139","author":"Kim","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib83","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib84","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186882","article-title":"Design and validation of linkers for site-specific preparation of antibody-drug conjugates carrying multiple drug copies per cysteine conjugation site","volume":"21","author":"Kumar","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105015_bib86","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105015_bib87","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2025.105015_bib88","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/1535-7163.MCT-19-0207","article-title":"A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine","volume":"18","author":"Le Joncour","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib89","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1309\/AJCPIRL4GUVGK3YX","article-title":"HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer","volume":"142","author":"Lee","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"issue":"S91","key":"10.1016\/j.critrevonc.2025.105015_bib90","article-title":"MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC","volume":"17","author":"Levy","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib91","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib92","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ccell.2019.05.010","article-title":"A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"35","author":"Li","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.105015_bib93","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib94","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105015_bib95","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2021.09.023","article-title":"An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer","volume":"163","author":"Liu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib96","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/2767-9764.CRC-24-0620","article-title":"Diverse ERBB2\/ERBB3 activating alterations and coalterations have implications for HER2\/3-targeted therapies across solid tumors","volume":"5","author":"Liu","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2025.105015_bib97","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib98","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib99","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.105015_bib100","first-page":"1626","article-title":"Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins from hamsters inoculated with such leukemia by heterografts","volume":"246","author":"Mathe","year":"1958","journal-title":"Comptes Rendus Hebd. Des. Seances De. l\u2032Acad. Des. Sci."},{"key":"10.1016\/j.critrevonc.2025.105015_bib101","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam, F., Hamilton, E.P., Beeram, M., Hanna, D.L., El-Khoueiry, A.B., Kang, Y.-K., Lee, K.W., Lee, J., Rha, S.Y., Chaves, J.M., et al. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study. Journal of Clinical Oncology 39, 164-164.","DOI":"10.1200\/JCO.2021.39.3_suppl.164"},{"key":"10.1016\/j.critrevonc.2025.105015_bib102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","article-title":"Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer","volume":"151","author":"Moore","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib103","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.105015_bib104","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105015_bib105","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae030","article-title":"Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations","volume":"8","author":"Necchi","year":"2024","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.critrevonc.2025.105015_bib106","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/2050-6511-14-32","article-title":"Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells","volume":"14","author":"Pallis","year":"2013","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004704","article-title":"GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies","volume":"10","author":"Pascual-Pasto","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib108","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13058-019-1186-0","article-title":"A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)","volume":"21","author":"Patel","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib109","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-20-0014","article-title":"First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer","volume":"20","author":"Pegram","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib110","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.critrevonc.2025.105015_bib111","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody-drug conjugates: current status and future directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2025.105015_bib112","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12885-019-5687-0","article-title":"Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine \u00b1 pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer","volume":"19","author":"Perez","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib113","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Investig. N. Drugs"},{"key":"10.1016\/j.critrevonc.2025.105015_bib114","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1158\/1078-0432.CCR-13-0358","article-title":"Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy","volume":"20","author":"Phillips","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib115","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to Trastuzumab in Breast Cancer","volume":"15","author":"Pohlmann","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib116","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of action of therapeutic antibodies for cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib117","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib118","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 Is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053518","article-title":"AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin","volume":"8","author":"Rosen","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.critrevonc.2025.105015_bib120","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib121","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/255487a0","article-title":"Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage","volume":"255","author":"Rowland","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.105015_bib122","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.105015_bib123","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41388-017-0108-9","article-title":"Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2\/xL in HER2-positive breast cancer","volume":"37","author":"Saatci","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2025.105015_bib124","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","article-title":"Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer","volume":"23","author":"Sabbaghi","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib125","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s12282-018-0861-9","article-title":"HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer","volume":"25","author":"Sakai","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib126","first-page":"22","article-title":"Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer","volume":"7","author":"Saleh","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.critrevonc.2025.105015_bib127","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.617","article-title":"Characterization of T-DM1-resistant breast cancer cells","volume":"8","author":"Sauveur","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.critrevonc.2025.105015_bib128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2025.105015_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163996","article-title":"Overcoming resistance to HER2-directed therapies in breast cancer","volume":"14","author":"Schlam","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.105015_bib130","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2021.39.15_suppl.1023","article-title":"BEGONIA: Phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple-negative breast cancer (TNBC)\u2014Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd)","volume":"39","author":"Schmid","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib131","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2022.40.16_suppl.105","article-title":"Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers","volume":"40","author":"Schram","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib132","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx065","article-title":"An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression","volume":"109","author":"Schwarz","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2025.105015_bib133","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.2024.42.16_suppl.1091","article-title":"Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): updated phase 2 safety and efficacy results","volume":"42","author":"Seneviratne","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib134","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1535-7163.MCT-11-0115","article-title":"Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models","volume":"10","author":"Sharkey","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA501","article-title":"Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial","volume":"42","author":"Shatsky","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib136","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1200\/JCO.2023.41.16_suppl.4566","article-title":"Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b\/2 study","volume":"41","author":"Sheng","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib137","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib138","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"ARX788, a Site-specific Anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib139","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1535-7163.MCT-06-0026","article-title":"Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin\/p97","volume":"5","author":"Smith","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib140","doi-asserted-by":"crossref","first-page":"B016","DOI":"10.1158\/1538-7445.PRCA2023-B016","article-title":"Abstract B016: Liquid biopsy biomarker analysis of a phase II trial of sacituzumab govitecan in castrate resistant metastatic prostate cancer","volume":"83","author":"Sperger","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib141","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-021-00311-y","article-title":"Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer","volume":"7","author":"Spring","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib142","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib143","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib144","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/acs.bioconjchem.7b00785","article-title":"Modulating antibody-drug conjugate payload metabolism by conjugation site and linker modification","volume":"29","author":"Su","year":"2018","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.critrevonc.2025.105015_bib145","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.critrevonc.2025.105015_bib146","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105015_bib147","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.105015_bib148","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib149","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105015_bib150","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/annonc\/mdw424","article-title":"Antibody drug conjugates: lessons from 20 years of clinical experience","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib151","doi-asserted-by":"crossref","unstructured":"Tripathy, D., Ali, K., Agrawal, L., Ali, S.M., Blau, S., Block, M., Danso, M.A., Yardley, D., Andersen, J., Waks, A.G., , 2024. ACE-BREAST-03: a phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd). 42, pp. TPS1123-TPS1123..","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1123"},{"key":"10.1016\/j.critrevonc.2025.105015_bib152","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.critrevonc.2025.105015_bib153","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib154","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105015_bib155","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.critrevonc.2025.105015_bib156","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood-2003-11-3825","article-title":"The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin","volume":"103","author":"Walter","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105015_bib157","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/s41416-020-0952-1","article-title":"YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer","volume":"123","author":"Wang","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105015_bib158","doi-asserted-by":"crossref","first-page":"18124","DOI":"10.1021\/acs.jmedchem.4c01251","article-title":"Exo-cleavable linkers: enhanced stability and therapeutic efficacy in antibody-drug conjugates","volume":"67","author":"Watanabe","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2025.105015_bib159","doi-asserted-by":"crossref","first-page":"38696","DOI":"10.1021\/acsomega.5c03755","article-title":"Biological evaluation of cleavable linkers in exatecan-based antibody-drug conjugates: a comparative study of DXd and Exo-linker platforms","volume":"10","author":"Watanabe","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.critrevonc.2025.105015_bib160","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214278119","article-title":"Tumor-targeted delivery of a STING agonist improvescancer immunotherapy","volume":"119","author":"Wu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2025.105015_bib161","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/1541-7786.MCR-12-0155-T","article-title":"Expression of Wnt3 activates Wnt\/\u03b2-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells","volume":"10","author":"Wu","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib162","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105015_bib163","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00456","article-title":"Phase Ib SEASTAR study: combining rucaparib and sacituzumab govitecan in patients with cancer with or without mutations in homologous recombination repair genes","author":"Yap","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib164","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib166","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","article-title":"A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs","volume":"21","author":"Yu","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105015_bib167","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41420-022-01259-z","article-title":"Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft","volume":"8","author":"Zhang","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.critrevonc.2025.105015_bib168","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e15013","article-title":"Preclinical antitumor activity of an anti-HER2\/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor","volume":"41","author":"Zhong","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105015_bib169","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070672","article-title":"Site-specific antibody conjugation to engineered double cysteine residues","volume":"14","author":"Zhou","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.critrevonc.2025.105015_bib170","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/1535-7163.MCT-18-0743","article-title":"Neutralization of BCL-2\/X(L) enhances the cytotoxicity of T-DM1 in vivo","volume":"18","author":"Zoeller","year":"2019","journal-title":"Mol. Cancer Ther."}],"updated-by":[{"DOI":"10.1016\/j.critrevonc.2026.105343","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000}},{"DOI":"10.1016\/j.critrevonc.2026.105343","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:15:24Z","timestamp":1778962524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":170,"alternative-id":["S1040842825004032"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105015","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-drug conjugates in oncology: A spotlight on overcoming resistance","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105015"}}